Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.
While much of the research at ESMO is based on breaking new ground and upping the ante against cancer, some studies focus on fine-tuning existing treatment to improve patient quality of lif
New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.
Clovis has confirmed a major victory with its ovarian cancer treatment Rubraca, the drug showing significant benefits for all patients in a maintenance setting – and better results than its
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho